START Midwest team has successfully dosed all three patients in the first cohort of the LOXO-FRA-24001 (J5E-OX-JZXA) trial

The START Center for Cancer Research shared on LinkedIn:          .

“We are proud to announce that our START Midwest team has successfully dosed all three patients in the first cohort of the LOXO-FRA-24001 (J5E-OX-JZXA) trial.

This innovative study, in collaboration with Loxo@Lilly, evaluates an antibody drug conjugate targeting folate receptor alpha with a topoisomerase 1 inhibitor payload.

Dr. Nehal Lakhani, Director of Clinical Research at START Midwest, shares, ‘Dosing the first cohort in the LOXO-FRA-24001 trial marks a significant achievement for our team. This study exemplifies our ongoing commitment to pioneering advanced treatments in oncology.’

Read more about this study.”

Source: The START Center for Cancer Research/LinkedIn